Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 12—December 2023
Research

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023

Todd G. SmithComments to Author , Crystal M. Gigante, Nhien T. Wynn, Audrey Matheny, Whitni Davidson, Yong Yang, Rene Edgar Condori, Kyle O’Connell, Lynsey Kovar, Tracie L. Williams, Yon C. Yu, Brett W. Petersen, Nicolle Baird, David Lowe, Yu Li, Panayampalli S. Satheshkumar, and Christina L. Hutson
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (T.G. Smith, C.M. Gigante, N.T. Wynn, A. Matheny, W. Davidson, Y. Yang, R.E. Condori, K. O’Connell, L. Kovar, T.L. Williams, Y.C. Yu, B.W. Petersen, N. Baird, D. Lowe, Y. Li, P.S. Satheshkumar, C.L. Hutson); Deloitte Consulting LLC, Arlington, Virginia, USA (K. O’Connell); Leidos Inc., Reston, Virginia, USA (L. Kovar)

Main Article

Figure 1

Geographic distribution of patients with mpox who had samples received for tecovirimat resistance testing (A) and who had samples confirmed resistant (B) June 2022–July 2023, United States.

Figure 1. Geographic distribution of patients with mpox who had samples received for tecovirimat resistance testing (A) and who had samples confirmed resistant (B) June 2022–July 2023, United States.

Main Article

Page created: October 18, 2023
Page updated: November 18, 2023
Page reviewed: November 18, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external